Skip to main content

Table 2 Univariate survival analysis

From: Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients

A. Variable

 

Disease specific survival

Overall survival

 

No.Patients

P

No.Patients

P

 

(died/total)

(logrank-Test)

(died/total)

(logrank-Test)

Size

T1

198/842

<0.001

307/842

<0.001

T2/3

414/1082

 

560/1082

 

LN

negative

234/1007

<0.001

386/1007

<0.001

positive

383/929

 

488/929

 

Tumour grade

I

27/163

<0.001

50/163

<0.001

II

208/767

 

315/767

 

III

365/947

 

473/947

 

Histology

invasive lobular

48/147

<0.001

69/147

<0.001

invasive ductal

520/1548

 

727/1548

 

special differentiation

20/148

 

41/148

 

lobular and ductal mixed forms

27/90

 

36/90

 

only “invasive tumour” as information

4/9

 

4/9

 

MP

premenopausal

141/428

0.877

152/428

<0.001

postmenopausal

472/1503

 

719/1503

 

HER2

neg

199/667

<0.001

287/667

<0.001

pos

61/147

 

73/147

 

ER

neg

183/432

<0.001

213/432

0.001

pos

429/1482

 

653/1482

 

Chemotherapy

no

433/1526

<0.001

682/1526

<0.001

yes

186/416

 

195/416

 

Radiation therapy

no

265/781

0.461

396/781

0.028

yes

354/1161

 

481/1161

 

Endocrine therapy

no

255/733

0.820

343/733

0.024

yes

364/1209

 

534/1209

 

NFE2L2 mRNA expression

low (<65th %ile)

453/1268

0.005

641/1268

0.003

high (>65th %ile)

166/674

 

236/674

 

NFE2L2 mRNA expression in ER pos tumours

low (<65th %ile)

318/968

0.013

485/968

0.004

high (>65th %tile)

111/514

 

168/514

 

B. Variable

 

Relapse-free survival

Overall survival

 

No.Patients

P

No.Patients

P

 

(relapsed/total)

(logrank-Test)

(died/total)

(logrank-Test)

Size

T1

12/68

0.022

17/68

0.006

T2/3/4

37/108

 

56/108

 

LN

negative

14/74

0.026

22/74

0.003

positive

33/96

 

47/96

 

Tumour grade

I

3/27

0.154

15/27

0.764

II

34/115

 

42/115

 

III

12/32

 

15/32

 

Histology

invasive lobular carcinoma

5/22

0.288

5/22

0.487

invasive ductal carcinoma

41/135

 

59/135

 

ductal carcinoma with specific differentiation

3/19

 

9/19

 

MP

premenopausal

14/48

0.970

14/48

0.032

postmenopausal

35/128

 

59/128

 

HER2

neg

36/133

0.971

51/133

0.692

pos

12/40

 

20/40

 

ER

neg

20/49

0.061

26/49

0.831

pos

29/127

 

47/127

 

PR

neg

24/59

0.021

32/59

0.234

pos

25/117

 

41/117

 

Chemotherapy

no

18/90

0.022

35/90

0.382

yes

31/86

 

38/86

 

Radiation therapy

no

14/68

0.348

33/68

0.069

yes

35/107

 

40/107

 

Endocrine therapy

no

18/51

0.232

30/51

0.433

yes

31/125

 

43/125

 

NFE2L2 mRNA expression

low (<65th %ile)

39/114

0.013

55/114

0.081

high (>65th %ile)

10/62

 

18/62

 

low (< median)

36/88

<0.001

48/88

0.004

high (> median)

13/88

 

25/88

 

NFE2L2 mRNA expression in ER pos tumours

low (<65th %ile)

25/82

0.005

37/82

0.034

high (>65th %ile)

4/45

 

10/45

 

low (< median)

23/59

<0.001

32/59

<0.001

high (> median)

6/68

 

15/68

 
  1. (A) Disease specific and overall survival in 1942 breast cancer patients in the METABRIC dataset. (B) Relapse-free and overall survival in 176 patients with primary breast cancer
  2. Bold values have a significance level of P < 0.05